Use of FGF19 amplification for evaluating and / or predicting sensitivity of esophageal cancer patients to fluorouracil chemotherapy
FGF19 gene was screened through esophageal oncogene sequencing, and it was found that its amplification and esophageal cancer cells were reduced in sensitivity to fluorouracil chemotherapy, providing a new biomarker to solve the problem of esophageal cancer cells' resistance to chemotherapy drugs and help screen for sensitivity population and improve chemotherapy effects.
Patent Information
- Application Number
- CN202410984974.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, esophageal cancer cells are resistant to conventional chemotherapy drugs, especially patients with advanced esophageal cancer are insensitive to fluorouracil drugs, resulting in poor chemotherapy effects and lack of effective biomarkers for predicting chemotherapy sensitivity.
FGF19 gene was screened through esophageal oncogene sequencing, and its characteristics and prognostic effects in esophageal cancer were analyzed. It was found that FGF19 amplification as a biomarker can predict the sensitivity of esophageal cancer cells or patients to fluorouracil chemotherapy, and was designed to detect FGF19 Kits of genes or their mRNA or proteins for evaluating and predicting chemotherapy sensitivity.
FGF19 amplification indicates that esophageal cancer cells or patients have reduced sensitivity to fluorouracil chemotherapy, providing a new biomarker that can help screen sensitive populations, improve chemotherapy effects, and has clinical medical transformation value.
Smart Images

Figure CN118910256A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to evaluating and / or predicting the sensitivity of esophageal cancer cells or esophageal cancer patients to chemotherapy based on biomarkers. More specifically, the present invention relates to evaluating and / or predicting the sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy based on gene markers or their mRNA or proteins or protein fragments encoded therein. Background Art
[0002] At present, clinical intervention measures for esophageal cancer mainly include surgery, radiotherapy, chemotherapy and drug therapy. Chemotherapy runs through the entire process of esophageal cancer treatment, including neoadjuvant chemotherapy, adjuvant chemotherapy, concurrent chemotherapy, palliative chemotherapy, etc. It has been found in clinical practice that many patients with advanced esophageal cancer are insensitive to chemotherapy. The types of chemotherapy drugs currently used for esophageal cancer are also limited. The more widely used ones include fluorouracil and fluorouracil-like drugs, taxanes and platinums. In addition, most patients with advanced esophageal cancer have undergone multiple lines of treatment, and the residual tumor cells after layers of treatment and screening are mostly tumor cells that are resistant to conventional chemotherapy drugs.
[0003] Therefore, solving the problem of esophageal cancer cell resistance to conventional chemotherapy drugs is an important topic in the field of esophageal cancer research. However, there is currently a lack of effective in vitro and in vivo models to study biomarkers for predicting sensitivity to targeted drugs, resulting in many drugs being unable to accurately screen sensitive populations, greatly affecting the advancement of drug clinical trials. Summary of the invention
[0004] In order to address the deficiencies of the prior art, the inventors of the present application screened new targets for the treatment of esophageal cancer based on the gene sequencing results of clinical esophageal cancer patients; and screened out a suitable variant gene FGF19 through esophageal cancer gene sequencing data. Then, the inventors of the present application analyzed the characteristics of the FGF19 gene in esophageal cancer and its effect on prognosis through the database, and analyzed that FGF19 may have the potential to be a target. Finally, the inventors of the present application found through in vivo and in vitro experiments that FGF19 amplification causes esophageal cancer cells to be resistant to fluorouracil. Based on this, the inventors of the present application found that FGF19 can be used as a key biomarker for clinical evaluation and / or prediction of reduced sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy, and has great clinical medical transformation value.
[0005] The present invention generally relates to the use of FGF19 amplification as a biomarker for evaluating and / or predicting the sensitivity of esophageal cancer cells or esophageal cancer patients to fluorouracil chemotherapeutic agents.
[0006] In one aspect, the present invention relates to the use of an agent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded thereof in the preparation of a kit for evaluating and / or predicting the sensitivity of esophageal cancer cells or patients suffering from esophageal cancer to fluorouracil chemotherapy or fluorouracil chemotherapeutic agents or fluorouracil, wherein compared with the control, an increased expression level and / or copy number amplification of the FGF19 gene indicates that the esophageal cancer cells or patients suffering from esophageal cancer have a decreased sensitivity to fluorouracil chemotherapy or fluorouracil chemotherapeutic agents or fluorouracil.
[0007] Fluorouracil chemotherapy referred to herein refers to chemotherapy using a fluorouracil chemotherapeutic agent. The fluorouracil chemotherapeutic agent referred to herein refers to fluorouracil, which is also known as 5-fluorouracil, and has the structural formula:
[0008] As described in detail in the definition section below, a person skilled in the art will understand the meaning of a control and how to set a control. For example, a control may be a healthy esophageal cell without FGF19 gene amplification, or a diseased cell unrelated to FGF19 gene amplification, such as an esophageal cancer cell in the early stage of the disease or a patient with esophageal cancer whose sensitivity to fluorouracil chemotherapy is not reduced.
[0009] FGF19 amplification referred to herein has the same meaning as FGF19 gene amplification, covering FGF19 gene copy number amplification and increased expression level, etc. Those skilled in the art also understand how to judge "increase" and / or "amplification", as described in detail in the definition section below, the increase and / or amplification is statistically significant, such as at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more increase and / or amplification, such as copy number amplification.
[0010] It is within the technical scope of those skilled in the art to design or select oligonucleotide probes, primers or antibodies for detecting FGF19 gene amplification and other reagents and methods for implementing the detection based on the FGF19 gene sequence (NM_005117) or the corresponding mRNA and protein sequences.
[0011] In some embodiments, the reagent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded by it includes a binding agent that binds to the protein or protein fragment encoded by the FGF19 gene, or a substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA.
[0012] In some embodiments, the binding agent that binds to the protein or protein fragment encoded by the FGF19 gene is an anti-FGF19 antibody.
[0013] In some embodiments, the substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA includes or consists of an oligonucleotide probe or primer.
[0014] Based on the teachings of the present invention, those skilled in the art may also select any other technical means and reagents that can detect the FGF19 gene or its mRNA or its encoded protein or protein fragment.
[0015] In another aspect, the present invention relates to a kit for evaluating and / or predicting the sensitivity of esophageal cancer cells or patients suffering from esophageal cancer to fluorouracil chemotherapy, wherein the kit comprises a reagent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded therein.
[0016] In some embodiments, the reagent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded by it includes a binding agent that binds to the protein or protein fragment encoded by the FGF19 gene, or a substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA.
[0017] In some embodiments, the binding agent that binds to the protein or protein fragment encoded by the FGF19 gene is an antibody against FGF19. Those skilled in the art can reasonably determine any anti-FGF19 antibody that can achieve the purpose of detection, such as a monoclonal antibody, a polyclonal antibody, a single-chain antibody, etc. or an antibody fragment thereof, according to the purpose of detection and actual conditions; the antibody can be a mouse antibody, a human antibody, etc.
[0018] In some embodiments, the substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA includes a probe or an oligonucleotide primer, or consists of the same.
[0019] In some embodiments, the esophageal cancer is esophageal squamous cell carcinoma or esophageal adenocarcinoma.
[0020] In some embodiments, the esophageal cancer is esophageal squamous cell carcinoma.
[0021] In some embodiments, the esophageal cancer is selected from recurrent esophageal cancer, metastatic esophageal cancer, recurrent metastatic esophageal cancer, and advanced metastatic esophageal cancer.
[0022] In yet another aspect, the present invention relates to a method for evaluating and / or predicting the sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy or a fluorouracil chemotherapeutic agent or fluorouracil, comprising the following steps:
[0023] (1) obtaining a biological sample from a subject; and
[0024] (2) detecting the expression level and / or copy number of the FGF19 gene or its mRNA or its encoded protein or protein fragment in the sample;
[0025] Compared with the control, increased expression level and / or copy number amplification of the FGF19 gene indicates that the esophageal cancer cells or patients with esophageal cancer have reduced sensitivity to fluorouracil chemotherapy.
[0026] In one embodiment, the biological sample is ctDNA, tumor tissue, tumor circulating cells, or tissue from other sources in the human body.
[0027] Those skilled in the art can reasonably select and determine appropriate detection techniques according to the detection purpose and actual situation. Suitable for different detection targets, the detection techniques may include but are not limited to gene sequencing, PCR, FISH, immunohistochemistry, ELISA, Western or flow cytometry.
[0028] As shown in the Examples section below, anlotinib can reverse (compared with the control) the decreased sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy caused by increased expression levels and / or amplified copies of the FGF19 gene. Thus, in another aspect of the present invention, the present invention relates to the use of anlotinib to prepare a drug for increasing (compared with the control) the sensitivity of esophageal cancer cells or patients with esophageal cancer with FGF19 gene amplification (including increased expression levels and / or amplified copies of the FGF19 gene) to fluorouracil chemotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 : The results of gene sequencing of 50 patients with esophageal cancer show the top 16 gene mutations and mutation frequencies. Among them, it shows that the mutation type of FGF19 gene in esophageal cancer is gene amplification, ranking third.
[0030] Figure 2 :Database analysis of FGF19-related features. A. cBioPortal website analysis of the proportion of FGF19 gene amplification in esophageal cancer datasets; B. GeneMANIA database analysis of 20 genes related to FGF19; C. STRING database analysis of 10 proteins related to FGF19; D. KEGG pathway enrichment analysis of FGF19+20 related genes; E. KEGG pathway enrichment analysis of FGF19+10 related proteins.
[0031] Figure 3:FGF19 is differentially expressed in esophageal cancer tissues and normal tissues. A. TCGA pan-cancer analysis showed that FGF19 was highly expressed in a variety of cancer tissues; B. FGF19 was significantly highly expressed in esophageal cancer tissues; C. ROC curve of FGF19 expression predicted esophageal cancer tumor tissues drawn using TCGA database (AUC = 0.788); D. ROC curve of FGF19 expression predicted esophageal cancer tumor tissues drawn using TCGA + GTEx database (AUC = 0.914).
[0032] Figure 4 : Successfully constructed an esophageal cancer cell line containing FGF19 gene amplification. A. qPCR experiments and protein immunoblotting experiments confirmed that the FGF19 amplified esophageal cancer cells were successfully constructed (KYSE-410FGF19 AM and KYSE-510FGF19 AM ); B. FGF19 gene amplification promotes the proliferation of esophageal cancer cells. The control group was the corresponding empty-loaded esophageal cancer cell lines (KYSE-410CON and KYSE-510CON).
[0033] Figure 5 :Transwell assay determined that FGF19 amplification significantly enhanced the invasion ability of esophageal cancer cells.
[0034] Figure 6 : FGF19 amplification significantly enhanced the migration ability of esophageal cancer. Figure 4 and Figure 5 .
[0035] Figure 7 :The effect of FGF19 amplification on the cell cycle of esophageal cancer cells, and the effect of fluorouracil (5μg / ml) and anlotinib (5μM) treatment on the cell cycle. A. Cell cycle distribution of KYSE-410CON esophageal cancer cells in each treatment group; B. KYSE-410FGF19 AM Cell cycle distribution of esophageal cancer cells in each treatment group; C. Cell cycle distribution of KYSE-510CON esophageal cancer cells in each treatment group; D. KYSE-510FGF19 AM Cell cycle distribution of esophageal cancer cells in each treatment group.
[0036] Figure 8 :FGF19 amplification reduces the sensitivity of esophageal cancer cells to fluorouracil, and anlotinib can enhance the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. The legends in the bar graph represent from top to bottom: control group / 5-fluorouracil, FGF19 amplification / 5-fluorouracil, FGF19 amplification / 5-fluorouracil + anlotinib (3 μM in the left bar graph and 1 μM in the right bar graph).
[0037] Fig. 9 :FGF19 amplification reduces the sensitivity of esophageal cancer cells to fluorouracil, and FGFR4 specific inhibitor FGF401 enhances the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. The legends in the bar graph represent from top to bottom: control group / 5-fluorouracil, FGF19 amplification group / 5-fluorouracil, FGF19 amplification / 5-fluorouracil+FGF401 (10μM).
[0038] Fig.10 : Exploration of FGF19-FGFR4 downstream signaling pathway. A. Western blotting assay to detect changes in protein expression in different treatment groups; B. CCK8 assay to detect the effect of FGF19 amplification on Wnt pathway inhibition (LGK974 is a Wnt pathway inhibitor). The legends in Figure C represent from top to bottom: control group, 5-fluorouracil (3μg / ml), 5-fluorouracil (3μg / ml) + LGK974 (10μM), 5-fluorouracil (3μg / ml) + anlotinib (3μM in the left column and 1μM in the right column). Fig.11 :The nude mouse subcutaneous transplant tumor model verifies the effect of FGF19 amplification on the sensitivity of esophageal cancer cells to fluorouracil chemotherapy. The legends in the left line graph represent from top to bottom: control group / blank control, control group / 5-fluorouracil, FGF19 amplification group / blank control, FGF19 amplification group / 5-fluorouracil, FGF19 amplification group / anlotinib, FGF19 amplification group / 5-fluorouracil+anlotinib.
[0039] Fig.12 :Immunohistochemical staining (Ki 67, CD31, TUNEL) of subcutaneous tumor tissues in nude mice. In Figure B, the groups from top to bottom are: control group / blank control, control group / 5-fluorouracil, FGF19 amplification group / blank control, FGF19 amplification group / 5-fluorouracil, FGF19 amplification group / anlotinib, FGF19 amplification group / 5-fluorouracil+anlotinib.
[0040] Fig.13 : Map of plasmid pcDNA3.1-FGF19. DETAILED DESCRIPTION
[0041] The present invention relates to the relationship between the expression and / or copy number of a newly discovered biomarker (i.e., FGF19) and the sensitivity of esophageal cancer, especially esophageal squamous cell carcinoma, to fluorouracil chemotherapy. The biomarkers described herein provide methods and uses for evaluating and / or predicting the effect of fluorouracil on the treatment of esophageal cancer. Therefore, one embodiment of the present invention represents an improvement in a biomarker, which is suitable for evaluating and / or predicting the effect of fluorouracil on the treatment of esophageal cancer. In another embodiment, the newly discovered biomarker of the present invention (i.e., FGF19) can be used in combination with one or more other cancer markers known in the art (e.g., CEA, CA 19-9, CA 125, CA 72-4, SCC, CF21-1, TSGF, P53-Ab, VEGFR2, VEGFA, CD24), for example, for evaluating and / or predicting the effect of fluorouracil on the treatment of esophageal cancer or for preparing a kit for this purpose.
[0042] The present invention discovered and confirmed that FGF19 amplification (e.g., increased gene copy number) is a key biomarker for predicting sensitivity to fluorouracil chemotherapy in esophageal squamous cells, suggesting that FGF19 has the potential to become a key biomarker for clinical evaluation and / or prediction of reduced sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy, and has huge exploration potential and application prospects.
[0043] Based on the important role of gene mutation in the development of cancer, targeted therapy is an effective means to curb the development of cancer. On the other hand, due to the complexity of organisms and diseases, it is not always possible to accurately identify target genes that can be used to effectively treat cancer. At present, radiotherapy and chemotherapy are still widely used means for cancer. However, clinically, many patients with advanced esophageal cancer are insensitive to the more widely used chemotherapy agent fluorouracil. In addition, most patients with advanced esophageal cancer have undergone multi-line treatment, and the residual tumor cells after layer-by-layer treatment screening are mostly tumor cells that are resistant to conventional chemotherapy drugs. The present invention provides a novel technical solution to solve the problem of esophageal cancer cells being resistant to conventional chemotherapy drugs, and provides more valuable survival opportunities for patients with esophageal cancer, especially those in the advanced stage, whose pathogenic mechanism is not clear or completely clear, and who lack targeted therapy.
[0044] The inventors hope to clarify some concepts here. For example, mutant genes detected in cancer cells, even mutant genes used as biomarkers for detection, are not necessarily related to the drug resistance of cancer or tumors. There is no necessary connection between the two. As described in Example 1 of the present application, based on the frequency statistical analysis of the gene sequencing results of 50 patients with esophageal cancer, we found the top 16 mutant genes, among which the FGF19 mutant gene ranked only third, and the TP53 and CCND1 mutant genes ranked first and second respectively. The phenomenon that FGF19 gene amplification reduces the sensitivity of esophageal cancer cells to fluorouracil chemotherapy agents found in the present invention is unexpected.
[0045] definition
[0046] The term "sample" means a material known or suspected to express or contain a biomarker (i.e., FGF19) or a binding agent thereof, wherein the binding agent is, for example, an antibody specific to the biomarker (i.e., FGF19). The sample may be derived from a biological source ("biological sample"), such as a tissue (e.g., a biopsy sample), an extract, or a cell culture including a cell (e.g., a tumor cell), a cell lysate, and a biological or physiological fluid, such as whole blood, plasma, serum, saliva, cerebrospinal fluid, sweat, urine, milk, peritoneal fluid, etc. The sample obtained from the source or the sample after pretreatment to improve the sample characteristics (e.g., preparing plasma from blood, diluting mucus, etc.) can be used directly. In certain aspects of the present invention, the sample is a human physiological fluid, such as human serum. In certain aspects of the present invention, the sample is a biopsy sample, such as a tumor tissue or cell obtained by tissue examination. In certain aspects of the present invention, the sample is a malignant or normal tissue sample, such as a normal tissue sample adjacent to cancer.
[0047] The term "marker" as used herein refers to a molecule to be used as a target for analyzing a patient's experimental sample. Examples of such molecular targets are genes, proteins or polypeptides. Genes, proteins or polypeptides used as markers in the present invention are expected to include naturally occurring variants of the gene or protein and fragments of the gene or protein or the variant, in particular immunologically detectable fragments. Immunologically detectable fragments preferably contain at least 6, 7, 8, 10, 12, 15 or 20 consecutive amino acids of the marker polypeptide. It will be appreciated by those skilled in the art that proteins released by cells or present in the extracellular matrix may be damaged (e.g., during inflammation) and may be degraded or cut into such fragments. Certain markers are synthesized in an inactive form, which may subsequently be activated by proteolysis. As will be appreciated by the skilled person, proteins or fragments thereof may also exist as part of a complex. Such a complex may also be used as a marker in the sense of the present invention. Variants of marker polypeptides may be encoded by the same gene, but may differ in their isoelectric point (=PI) or molecular weight (=MW) or both, for example as a result of optional mRNA or mRNA precursor processing. The amino acid sequence of the variant has 95%, 96%, 97%, 98%, 99% or higher identity with the corresponding marker sequence. In addition, or in the alternative, the marker polypeptide or its variant may carry a post-translational modification. Non-limiting examples of post-translational modifications are glycosylation, acylation and / or phosphorylation.
[0048] The expression of the marker can also be identified by detecting the translation of the marker (i.e., detection of the marker protein in the sample). Methods suitable for detecting marker proteins include any suitable method for detecting and / or measuring proteins derived from cells or cell extracts. Such methods include, but are not limited to immunoblotting (such as Western blot), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunohistochemistry and immunofluorescence. Particularly preferred methods for detecting proteins include any cell-based assays, including immunohistochemistry and immunofluorescence assays. Such methods are well known in the art.
[0049] The terms "subject", "patient" and "individual" are used interchangeably herein and refer to warm-blooded animals, such as mammals. The term includes, but is not limited to, livestock, rodents (such as rats and mice), primates and humans. Preferably, the term refers to humans.
[0050] Fibroblast growth factor 19 (FGF19) was first discovered in the human brain. Its coding gene is located on chromosome 11q13 and consists of 216 amino acids. It is highly expressed in ileal and gallbladder epithelial cells, but cannot be detected in normal liver. FGF15 is highly expressed in the ileum, jejunum and duodenum of adult mice. It is the mouse homolog of FGF19 and consists of 218 amino acids. It has 51% similarity with human FGF19. The FGF19 gene discussed in this article refers to the human FGF19 gene whose sequence is shown in NCBI No. NM_005117.
[0051] The term "control" should be understood according to the general understanding of those skilled in the art, and represents any useful reference for comparing gene copy number, protein or mRNA level. The control can be any sample, standard, standard curve or level for comparison purposes. The control can be a normal reference sample or reference standard or level. The control can be a blood control sample of the patient himself; the expression of an internal reference gene (such as FGF19) of esophageal cancer such as esophageal squamous cell carcinoma tumor cells themselves; predetermined cells that are relatively insensitive to fluorouracil (e.g., primary esophageal squamous cell carcinoma cells that are relatively insensitive to fluorouracil), such as "normal control" or a previous sample taken from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (e.g., cell or tissue) from a subject without the disease; or a sample of a purified protein or RNA at a known normal concentration. "Reference standard or level" refers to a value or number derived from a reference sample. "Normal control value" is a predetermined value indicating a non-disease state, for example, a value expected in a healthy control subject. Typically, a normal control value is expressed as a range ("between X and Y"), an upper threshold ("not higher than X"), or a lower threshold ("not lower than X"). For a particular biomarker, a subject with a measurement within the normal control value is often referred to as being "within normal limits" for that biomarker. A normal reference standard or level can be a normal subject who has never suffered from a disease or condition (e.g., cancer). The empty esophageal cancer cell lines (KYSE-410CON and KYSE-510CON) constructed in the examples herein are FGF19 amplified stably transfected esophageal cancer cell lines (KYSE-410FGF19) constructed. AM / KYSE-510FGF19 AM ) control group.
[0052] Compared to a control or standard (e.g., normal levels from healthy esophageal cells, levels at different stages of the disease or levels in other samples from patients, levels of esophageal cancer cells from previous stages of the disease or patients with esophageal cancer that have maintained undiminished sensitivity to fluorouracil), an "increase" or "decrease" in the expression level of a marker in a patient sample or an "amplification" or "deletion" in the copy number can mean a level that is higher or lower than the standard error of the detection assay, preferably at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more of the control or standard, or at most about 1 / 1.1, 1 / 1.25, 1 / 1.5, 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 6, 1 / 7, 1 / 8, 1 / 9 or 1 / 10 or less of the control or standard. Copy number amplification or deletion can be detected by techniques well known in the art, such as high-throughput sequencing as described in the examples, or whole genome sequencing, whole transcriptome sequencing, other second-generation sequencing detection methods, chip detection, droplet digital polymerase chain reaction (ddPCR), etc. as known in the art. FGF19 gene amplification referred to herein means that the copy number of the FGF19 gene is increased or the expression level is increased compared to the above-mentioned control or standard that does not contain amplification, preferably increased or increased by at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more.
[0053] The terms "polypeptide" and "protein" or "protein" are used interchangeably herein to refer to at least one molecular chain of amino acids linked by covalent and / or non-covalent bonds. The term includes peptides, oligopeptides and post-translational modifications of proteins and polypeptides, such as glycosylation, acetylation, phosphorylation, etc. Protein fragments, analogs, mutant proteins or variant proteins, fusion proteins, etc. are also included in the meaning of the term.
[0054] In the present invention, protein fragment refers to a polypeptide having an amino terminal deletion, a carboxyl terminal deletion and / or an intermediate deletion compared to the full-length native protein. The fragment may also contain modified amino acids compared to the native protein. In certain embodiments, the fragment length is about 5-215 amino acids. For example, the fragment length may be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150 or 200 amino acids. In one embodiment, the fragment is an immunologically detectable fragment, which preferably comprises at least 6, 7, 8, 10, 12, 15 or 20 consecutive amino acids of a marker polypeptide. The change of protein expression level refers to that compared with the expression level of control or standard, at least be at least about 1.1,1.25,1.5,2,3,4,5,6,7,8,9 or 10 times or more times of the expression level of control or standard or be at most about 1 / 1.1,1 / 1.25,1 / 1.5,1 / 2,1 / 3,1 / 4,1 / 5,1 / 6,1 / 7,1 / 8,1 / 9 or 1 / 10 or less of the expression level of control or standard.In this article, owing to the amplification of FGF19 gene, its corresponding RNA (such as mRNA) and protein expression or level can also be compared to control group and increase, for example, increase at least about 1.1,1.25,1.5,2,3,4,5,6,7,8,9 or 10 times or more times.
[0055] In certain embodiments, determination of "protein expression level", "gene expression" or "gene expression level" as used herein includes but is not limited to determination of corresponding RNA, protein or peptide levels (or a combination thereof). The present invention is not limited to specific methods and reagents for determining protein, peptide or RNA levels, all of which are well known in the art.
[0056] Methods for determining the amount or concentration of a protein in a sample are known to the skilled person. Such methods include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays. For methods using antibodies, both monoclonal and polyclonal antibodies are suitable. Such antibodies may be immunologically specific for a protein, protein epitope, or protein fragment.
[0057] The term "oligonucleotide" refers to a polymeric form of nucleotides of any length, which is a ribonucleotide or a deoxyribonucleotide. The term includes double-stranded and single-stranded DNA and RNA, such as modified forms and unmodified forms such as methylation or capping of polynucleotides. The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein. Oligonucleotides may include but are not necessarily other coding or non-coding sequences, or they may be but are not necessarily connected to other molecules and / or carriers or support materials. The oligonucleotides used in the methods of the present invention or kits may have any length suitable for a specific method. In certain applications, the term refers to an antisense nucleic acid molecule (e.g., an mRNA or DNA chain in the opposite direction of a sense polynucleotide encoding a cancer marker of the present invention (e.g., FGF19)).
[0058] Oligonucleotides used in the present invention include complementary nucleic acid sequences and nucleic acids substantially identical to these sequences, and also include sequences that are different from nucleic acid sequences due to genetic code degeneracy. Oligonucleotides that can be used in the present invention also include nucleic acids that hybridize to oligonucleotide cancer marker nucleic acid sequences under stringent conditions, preferably under high stringency conditions.
[0059] Nucleotide hybridization assays are well known in the art. Hybridization assay procedures and conditions will vary depending on the application and are selected based on known general binding methods, see, for example, J. Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd ed. Science Press, 2002); and Young and Davis, PNAS, 80:1194 (1983). Methods and apparatus for performing repeated and controlled hybridization reactions have been described in U.S. Pat. Nos. 5,871,928, 5,874,219, 6,045,996, 6,386,749 and 6,391,623, each of which is incorporated herein by reference.
[0060] In some cases, it may be necessary to amplify the sample. Genomic samples can be amplified by various mechanisms, some of which can use PCR. Samples can be amplified on an array. See, for example, U.S. Patent No. 6,300,070 and U.S. Patent Application Serial No. 09 / 513,300.
[0061] Other suitable amplification methods include ligase chain reaction (LCR) (e.g., Wu and Wallace, Genomics 4, 560 (1989), Landegren et al. Science 241, 1077 (1988), and Barringer et al. Gene 89: 117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86, 1173 (1989) and WO88 / 10315), self-sustaining sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA, 87, 1874 (1990) and WO90 / 06995), selective amplification of target polynucleotide sequences (U.S. Pat. No. 6,410,276), consensus sequence-primed polymerase chain reaction (CP-PCR) (U.S. Pat. No. 4,437,975), arbitrarily primed polymerase chain reaction (AP-PCR) (U.S. Pat. Nos. 5,413,909, 5,861,245), and nucleic acid-based sequence amplification (NABSA) (see U.S. Pat. Nos. 5,409,818, 5,554,517, and 6,063,603, each of which is incorporated herein by reference).
[0062] Reagents that can be used to detect the expression level and / or copy number of FGF19 are well known in the art. Such reagents suitable for use in the present invention can be purchased commercially or routinely prepared by methods well known to those skilled in the art.
[0063] The term "binding agent" refers to substances such as polypeptides, antibodies, ribosomes or aptamers that specifically bind to the biomarkers of the present invention (FGF19). If a substance reacts with the biomarkers of the present invention at a detectable level, but does not detectably react with peptides containing unrelated sequences or sequences of different polypeptides, it "specifically binds" to the biomarkers of the present invention. Binding properties can be evaluated by methods that can be easily performed by those skilled in the art, such as ELISA.
[0064] The binding agent may be a ribosome, RNA or DNA molecule or a polypeptide with or without a peptide component. The binding agent may be a polypeptide comprising a polypeptide biomarker sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence.
[0065] Aptamers include DNA or RNA molecules that bind to nucleic acids and proteins. Aptamers that bind to the markers of the present invention can be produced using conventional techniques without undue experimentation. [See, for example, the following publications describing in vitro selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].
[0066] Antibodies for use in the present invention include, but are not limited to, synthetic antibodies, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2), dAbs (domain antibodies; see Ward et al., 1989, Nature, 341:544-546), antibody heavy chains, intracellular antibodies, humanized antibodies, human antibodies, antibody light chains, single-chain Fvs (scFvs) (e.g., including monospecific, bispecific, etc.), anti-idiotypic (ant-Id) antibodies, proteins comprising antibody portions, chimeric antibodies (e.g., antibodies containing the binding specificity of a mouse antibody but in which the remainder is of human origin), derivatives such as enzyme conjugates or labeled derivatives, double-chain antibodies, linear antibodies, disulfide-linked Fvs (sdFvs), multispecific antibodies (e.g., bispecific antibodies), epitope-binding fragments of any of the above, and any other modified configurations of immunoglobulin molecules comprising an antigen recognition site of the desired specificity. Antibodies include antibodies of any type (e.g., IgA, IgD, IgE, IgG, IgM, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or any subclass (e.g., IgG2a and IgG2b), and the antibodies need not be of any particular type, class, or subclass. In certain embodiments of the invention, the antibody is an IgG antibody or a class or subclass thereof. The antibody may be from any animal source, including birds and mammals (e.g., humans, mice, donkeys, sheep, rabbits, goats, guinea pigs, camels, horses, or chickens).
[0067] For example, antibodies for use in the present invention are commercially available from, for example, BioVision (e.g., catalog number 5542R-100), Abcam (e.g., catalog number ab172545), etc. Alternatively, the antibodies can be prepared by recombinant methods known in the art. In some embodiments, the antibodies are monoclonal antibodies. For the preparation of monoclonal antibodies, see, for example, Kohler et al. (1975) Nature 256: 495-497; Kozbor et al. (1985) J. Immunol Methods 81: 31-42; Cote et al. (1983) Proc Natl Acad Sci 80: 2026-2030 and Cole et al. (1984) Mol Cell Biol 62: 109-120.
[0068] The kit according to the present disclosure can be prepared by conventional methods in the art. The kit may contain materials or reagents required for implementing the method or use of the present invention (including reagents for detecting the FGF19 gene or its mRNA or its encoded protein or protein fragment). The kit may include containers for storing reaction reagents (e.g., primers, dNTPs, enzymes, etc. in suitable containers) and / or support materials (e.g., buffers, instructions for implementing detection, etc.). For example, the kit may include one or more containers (e.g., boxes) for accommodating corresponding reaction reagents and / or support materials. Such contents can be applied to the sample to be detected together or separately. As an example, the kit may contain reagents, buffers, and instructions for use for detecting the FGF19 gene or its mRNA or its encoded protein or protein fragment. The kit may also contain polymerase and dTNP, etc. The kit may also contain internal standards, positive and negative controls, etc. for quality control. The kit may also contain reagents for preparing nucleic acids such as DNA from samples. The above examples are only used to more clearly illustrate the present invention, and do not constitute any limitation on the kits and contents thereof applicable to the present invention.
[0069] Example
[0070] In order to explain the content of the present invention more clearly, the following will be described in detail with reference to the accompanying drawings and embodiments.
[0071] Example 1 Screening of new therapeutic targets for esophageal cancer based on gene sequencing results of clinical esophageal cancer patients
[0072] In clinical work, we collected clinical data of esophageal cancer patients who underwent gene sequencing. We statistically analyzed the whole genome sequencing results of 50 esophageal cancer patients collected by the Animal Experiment Center of Nanfang Hospital and screened out new therapeutic targets.
[0073] The frequency statistical analysis of the gene sequencing results of 50 patients with esophageal cancer found that the top 16 variant genes were: TP53, CCND1, FGF19, NOTCH1, LRP1B, FAT1, MYC, CDKN2A, NSD1, EP300, CHEK2, ZNF217, PTCH1, DICER1, CBLB, GNAS. The types of gene mutations included: gene mutation, gene amplification, single copy number deletion, and gene fusion. The top three gene mutations and their proportions were: TP53 gene mutation accounted for 88%, CCND1 gene mutation accounted for 48% (among which amplification accounted for 46% and mutation accounted for 2%), and FGF19 gene amplification accounted for 46%. Figure 1 shown.
[0074] We screened out FGF19 as a new target for research.
[0075] Example 2 Database Analysis of FGF19 Gene Characteristics in Esophageal Cancer and Its Effect on Prognosis
[0076] Although the research results based on Example 1 show that FGF19 amplification has the potential to be a new target for precision treatment of esophageal cancer, it is necessary to further clarify whether the new target is significantly highly expressed in tumor tissues and whether it affects the prognosis of esophageal cancer patients. Therefore, this example further analyzes the characteristics of FGF19 in esophageal cancer patients and its effect on the prognosis of esophageal cancer patients through the sequencing results of a large sample size in an online database.
[0077] The proportion of FGF19 amplification in esophageal cancer was analyzed using the esophageal cancer dataset (TCGA, FirehoseLegacy) from the cBioPortal website. Gene-gene and protein-protein interaction network analysis of FGF19 was performed using the GeneMANIA and STRING websites, and pathway enrichment analysis of FGF19 gene-related genes and proteins was performed using KEGG. The differential expression of FGF19 in esophageal cancer tumor tissues and normal tissues was analyzed using the esophageal cancer dataset from the TCGA database. Genes positively and negatively correlated with FGF19 expression in esophageal cancer were screened using the LinkedOmics database, and the biological function enrichment analysis of FGF19 was performed. The clinical characteristics, prognosis analysis, and visualization of the esophageal cancer dataset from the TCGA database were performed using the R language.
[0078] R software was used for analysis. Independent sample t-test was used to analyze the differential expression level of FGF19 mRNA between esophageal cancer tissues and normal tissues in the TCGA database. Pearson chi-square test was used to analyze the correlation between FGF19 expression and clinicopathological characteristics. Kaplan-Meier plot was used for disease-specific survival (DSS) analysis, and log-rank test was used to compare differences. Cox proportional hazards regression model was used for univariate and multivariate analysis. Two-tailed P < 0.05 was considered statistically significant.
[0079] First, we analyzed the mutation of FGF19 gene in esophageal cancer through the database to understand its characteristics in esophageal cancer. We analyzed the TCGA database esophageal cancer data set (TCGA, Firehose Legacy) through the cBioPortal website and found that FGF19 amplification accounted for 35% in esophageal cancer ( Figure 2 A). Gene-gene and protein-protein interaction network analysis was performed using the GeneMANIA website and the STRING website, and 20 potential target genes interacting with the FGF19 gene were found (FGFR4 / KLB / KL / SDC2 / FGFR1 / FGF20 / FGF5 / FGF17 / FGF22 / FGF16 / FGF23 / FGF8 / FGF18 / FGF6 / FGF9 / FGF3 / FGF7 / FGF4 / FGF10 / FGF1)( Figure 2 B) and 10 potential target proteins (KLB / FGFR1 / FGFR3 / FGFR2 / FGF23 / FGF10 / FGF7 / FGF2 / PLCG1 / FGFR4) ( Figure 2 C) FGF19 and 20 related genes ( Figure 2 D) and 10 related protein-coding genes ( Figure 2 E) KEGG pathway enrichment analysis was performed separately, and it was found that the main enriched signaling pathways related to FGF19 at the gene and protein levels were PI3K-Akt signaling pathway and MAPK signaling pathway.
[0080] We analyzed the expression of FGF19 in pan-cancer in the TCGA database and found that FGF19 was differentially expressed in various tumor tissues and normal tissues ( Figure 3 A), the expression of FGF19 in esophageal cancer tissues was significantly higher than that in normal tissues ( Figure 3 B). In the process of tumor development, high expression of FGF19 can predict tumor tissue (AUC = 0.788) ( Figure 3 C), TCGA+GTEx database showed that high expression of FGF19 had a high accuracy in predicting tumor tissue (AUC = 0.914) ( Figure 3D). The above results suggest that FGF19 is significantly overexpressed in esophageal cancer tumor tissues and may serve as a new target for the treatment of esophageal cancer.
[0081] Example 3 FGF19 amplification reduces chemotherapy sensitivity of esophageal cancer cells
[0082] Using human esophageal cancer cell lines KYSE-410 and KYSE-510 purchased from Shanghai Meixuan Biotechnology Co., Ltd., we successfully constructed a stably transfected esophageal cancer cell line containing FGF19 amplification (KYSE-410FGF19 AM / KYSE-510FGF19 AM ), and empty vector esophageal cancer cell lines (KYSE-410CON / KYSE-510CON). The plasmid used is pcDNA3.1-FGF19 ( Fig.13 ), comprising the FGF19 gene inserted downstream of the CMV promoter, and with a puromycin resistance gene as a selection marker. The sequence of the FGF19 gene is the gene sequence shown in NCBI No.: NM_005117, and the gene fragment was synthesized by Jikai Biotechnology Co., Ltd. The empty plasmid is pcDNA3.1-empty, which contains the CMV promoter and the puromycin resistance gene, but does not have the FGF19 gene inserted. When the cells are cultured to 30-50% confluence, 50 μL of virus solution and 8 μg / ml polybrene are used for transfection. Fresh culture medium is replaced after 24-48 hours of culture. KYSE-410 cells and KYSE-510 cells are placed in complete culture medium containing 250 μg / ml and 450 μg / ml G418 for 5-7 days after transfection 48-96 hours later to obtain cells with G418 resistance, and then monoclonal stable transfection cell lines are screened and cultured.
[0083] Real-time quantitative PCR (qPCR) and Western blot were used to verify the mRNA level and protein level, respectively. Figure 4 As shown in A, the stably transfected esophageal cancer cell line containing FGF19 amplification had significantly higher FGF19 expression than the control group.
[0084] It was also found through clone formation experiments that FGF19 amplification promoted the proliferation of esophageal cancer cells. Stably transfected cells were seeded into 6-well culture dishes at a low density (500 cells / well) and cultured for two weeks, during which the culture medium was changed every 3 days. The cells were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of clones formed in each culture dish was counted and compared. The results are shown in Figure 2. Figure 4B. The experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0085] 3.1 FGF19 amplification enhances the invasive ability of esophageal cancer cells
[0086] After successfully constructing the FGF19-amplified esophageal cancer cell line, the effect of FGF19 amplification on the malignant biological characteristics of esophageal cancer cells was further verified. First, the effect of FGF19 amplification on the invasive ability of esophageal cancer cells was observed by Transwell invasion assay. The Transwell device used was purchased from Corning, with a pore size of 8 μm. The number of cells seeded was 5×10 4 Cells / well were inoculated in the upper chamber containing Matrigel (BD Biosciences), and culture medium containing 10% FBS was added to the lower chamber as a chemotactic factor. After 48 hours of culture, the non-migrated cells in the upper chamber were removed, and the migrated cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of migrated cells in each well was counted and compared with the control group (i.e., empty esophageal cancer cell line).
[0087] The results showed that FGF19 amplified esophageal cancer cells (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) had significantly stronger invasive ability than the control group (KYSE-410CON / KYSE-510CON). Figure 5 As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0088] 3.2 FGF19 amplification enhances the migration ability of esophageal cancer cells
[0089] The cells were cultured at 2 × 10 5The cells were seeded at a density of cells / well in a 6-well plate. When the cells grew to 80-90% confluence, a straight line was drawn on the cell monolayer with a 200μl pipette tip, and then the floating cells were gently washed away with PBS. Serum-free culture medium was added, and photos were taken at 0 hours, 24 hours, 48 hours and 72 hours to record the healing of the scratches. The scratch area was measured using ImageJ software, and the percentage of scratch healing was calculated. The results showed that the migration ability of esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19AM / KYSE-510FGF19AM) was significantly stronger than that of the control group (KYSE-410CON / KYSE-510CON). The results are as follows Figure 6 As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05, and ** represents P < 0.01.
[0090] 3.3 Effect of FGF19 amplification on the cell cycle of esophageal cancer cells
[0091] Next, we tested the effect of FGF19 amplification on the cell cycle of esophageal cancer cells, as well as the effect of anlotinib (5μM) and fluorouracil (5μg / ml) on the cell cycle of esophageal cancer cells. AM / KYSE-510FGF19 AM There was no significant difference in the cell cycle between the control group (KYSE-410CON / KYSE-510CON), but different drug treatments caused esophageal cancer cells to be blocked in different cell division phases. After fluorouracil treatment of cells, the cell cycle was mainly blocked in the S phase, while after anlotinib treatment of cells, the esophageal cancer cell cycle was mainly blocked in the G2 / M phase. Figure 7 These experimental results indicate that although FGF19 amplification does not significantly affect cell cycle distribution, the effects of 5-FU and anlotinib on the cell cycle are significant.
[0092] 3.4 In vitro verification that FGF19 amplification reduces fluorouracil chemotherapy sensitivity in esophageal cancer cells
[0093] Through the previous experimental results on the effects of FGF19 amplification on the biological characteristics of esophageal cancer cells such as invasion, migration, cell cycle, and apoptosis, we found that the esophageal cancer cells in the control group were sensitive to fluorouracil, and the use of fluorouracil could significantly inhibit the invasion function of the esophageal cancer cells in the control group; FGF19 amplification promoted the invasion and migration of esophageal cancer cells, but the use of fluorouracil had no significant inhibitory effect, while anlotinib or anlotinib combined with fluorouracil could significantly inhibit the invasion and migration of FGF19 amplified esophageal cancer cells. This suggests that FGF19 amplification leads to enhanced malignant biological behavior of esophageal cancer cells, and this enhancement also reduces the sensitivity of esophageal cancer cells to the chemotherapeutic agent fluorouracil, and anlotinib or anlotinib combined with fluorouracil can prevent this process.
[0094] Combined with our clinical research, that is, 4 patients with FGF19 amplification in clinical cases all achieved partial remission (PR) with anlotinib combined with fluorouracil drugs, we speculate that FGF19 amplification leads to fluorouracil resistance in esophageal cancer cells, and the combination of anlotinib can reverse this process.
[0095] To this end, the CCK8 assay was used to determine the effect of FGF19 amplification on the sensitivity of esophageal cancer cells to fluorouracil chemotherapy. AM / KYSE-510FGF19 AM ) were seeded in 96-well plates at a density of 1000 cells / well. After culturing for 24 hours, different concentrations of fluorouracil (0, 0.01, 0.03, 0.1, 0.3, 1, and 3 μg / ml) and anlotinib (KYSE-410FGF19 AM 3 μM, KYSE-510FGF19 AM 1 μM), treated alone or in combination for 120 hours. Then, 10 μl of CCK8 reagent (Dojindo) was added to each well, incubated at 37°C for 2 hours, and the absorbance was measured at a wavelength of 450 nm using an enzyme reader.
[0096] The experimental results are consistent with our speculation: compared with the control group (KYSE-410CON / KYSE-510CON), FGF19 amplified esophageal cancer cells (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) decreased the chemosensitivity to fluorouracil, while the combination with anlotinib could enhance the chemosensitivity to fluorouracil of FGF19 amplified esophageal cancer cells, and the two had a synergistic effect. Figure 8As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0097] 3.5FGF19 amplification reduces fluorouracil chemotherapy sensitivity in esophageal cancer cells via FGF19-FGFR4-AKT signaling pathway
[0098] The results of CCK8 experiments showed that the esophageal cancer cells in the control group (KYSE-410CON / KYSE-510CON) were sensitive to fluorouracil chemotherapy, while the esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) are insensitive to chemotherapy using fluorouracil.
[0099] Next, we further explored the molecular mechanism of decreased sensitivity to fluorouracil in FGF19-amplified esophageal cancer cells. It is well known that FGF401 is a specific inhibitor of FGFR4. We used FGF401 to block the downstream transmission of FGF19-FGFR4 signals. The results showed that when fluorouracil was combined with FGF401, the chemotherapy sensitivity of FGF19-amplified esophageal cancer cells to fluorouracil was restored. The above results indicate that FGF19 amplification leads to decreased sensitivity to fluorouracil by enhancing the FGFR4 signal. Therefore, after using FGF401 to specifically block FGFR4, the sensitivity of esophageal cancer cells to fluorouracil was restored. The results are as follows Fig. 9 The experimental comparison results were statistically significant based on the t-test. All P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001; ns represents no statistical significance.
[0100] At the same time, we also explored the downstream pathways of FGF19-FGFR4 signaling through Western blot experiments and CCK8 experiments. Combined with the main enrichment signaling pathways of FGF19-related proteins in Example 2, we verified the AKT and MAPK, STAT3, and Wnt signaling pathways through Western blot. The antibodies used for western blotting included p-AKT (Cell Signaling Technology, #4060, 1:1000 dilution), AKT (Cell Signaling Technology, #9272, 1:1000 dilution), p-ERK1 / 2 (Cell Signaling Technology, #4370, 1:1000 dilution), ERK1 / 2 (Cell Signaling Technology, #9102, 1:1000 dilution), p-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), STAT3 (Cell Signaling Technology, #9139, 1:1000 dilution), and β-actin (Cell Signaling Technology, #4970, 1:5000 dilution) as the internal control antibody.
[0101] The results showed that the expression levels of p-AKT, p-ERK1 / 2, and p-STAT3 did not change significantly after treatment with fluorouracil alone or in combination with anlotinib. Fig.10 As shown in A; however, after treating esophageal cancer cells with the Wnt pathway inhibitor LGK974, the inhibition efficiency of FGF19 amplified esophageal cancer cells was significantly stronger than that of the control group, as shown in Fig.10 As shown in B, LGK974 can enhance the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. There is no significant difference in the inhibition of cell proliferation when fluorouracil combined with LGK974 or anlotinib is used to treat FGF19 amplified esophageal cancer cells. Fig.10 As shown in C. Fig.10 The experimental comparison results of B and 10C were statistically significant based on t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; ns represents no statistical significance.
[0102] 3.6 In vivo verification of the effect of FGF19 amplification on fluorouracil chemotherapy sensitivity in esophageal cancer cells
[0103] Next, we used a nude mouse subcutaneous transplant tumor model to verify the effect of FGF19 amplification on the sensitivity of esophageal cancer to fluorouracil chemotherapy. A total of 60 female BALB / c nude mice aged 3-4 weeks (purchased from the Animal Experiment Center of Southern Medical University, Guangzhou, Guangdong Province, and raised in the SPF environment of the Animal Experiment Center of Southern Hospital) were selected and KYSE-410CON and KYSE-410FGF19 were injected into the nude mouse subcutaneous transplant tumor model. AM The cells were inoculated subcutaneously on the back of nude mice, with 5×10 5 After inoculation, wait until the tumor volume reaches about 150-250mm 3 Drug treatment was started at 1:00 pm. The nude mice were randomly divided into four groups (10 mice in each group): control group, fluorouracil treatment group (50 mg / kg, intraperitoneal injection, twice a week, for 2 weeks), anlotinib treatment group (0.3 mg / kg, gavage, once a day, for 14 days) and fluorouracil combined with anlotinib treatment group (same dosage as before). After the treatment, the nude mice were killed and the subcutaneous tumors were removed for size measurement.
[0104] The results showed that FGF19 amplified esophageal cancer cells (KYSE-410FGF19 AM ) subcutaneous tumors were less sensitive to fluorouracil (50 mg / kg / w×2w) than the subcutaneous transplanted tumors of esophageal cancer cells (KYSE-410CON) in the control group. However, after combined treatment with anlotinib (0.3 mg / kg / d×14d), the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil was significantly enhanced, showing drug synergy, which is consistent with our in vitro experimental results. Fig.11 The experimental comparison results were statistically significant based on the t-test. All P values were two-sided and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; ns represents no statistical significance.
[0105] After drug treatment, the nude mice were killed and the subcutaneous tumors were removed for further immunohistochemical staining. The antibodies used for immunohistochemistry included Ki67 antibody (Cell Signaling Technology, #9027, 1:200 dilution), CD31 antibody (Abcam, ab28364, 1:100 dilution) and TUNEL kit (Roche, #11684795910).
[0106] Immunohistochemistry results showed that the Ki67 positive rate of esophageal cancer cell transplanted tumors in the control group (KYSE-410CON) was significantly decreased after treatment with fluorouracil; while the Ki67 positive rate of esophageal cancer cell transplanted tumors in the FGF19 amplification group (KYSE-410FGF19 AM) The Ki67 positive rate did not decrease significantly after the transplanted tumors were treated with fluorouracil or anlotinib, but the Ki67 positive rate in the FGF19 amplified group esophageal cancer cells (KYSE-410FGF19 AM ) The Ki67 positive rate of transplanted tumors was significantly reduced. CD31 staining indicated that tumor blood vessels were positive in the transplanted tumor tissues. After the control group and the amplification group were treated with fluorouracil, there was no significant change in CD31 staining. After the esophageal cancer cells in the FGF19 amplification group were treated with anlotinib combined with fluorouracil, the esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19 AM )CD31 staining of transplanted tumors was significantly reduced. TUNEL staining showed little difference among the groups, but the positive rate of TUNEL staining was significantly increased after esophageal cancer cells in the FGF19 amplification group were treated with fluorouracil combined with anlotinib.
[0107] The above results show that fluorouracil can significantly inhibit the proliferation of esophageal cancer cells in the control group, while fluorouracil has no significant inhibitory effect on the proliferation of esophageal cancer cells in the FGF19 amplification group. However, the combination of fluorouracil and anlotinib can not only significantly inhibit the proliferation of esophageal cancer cells in the FGF19 amplification group, but also inhibit angiogenesis and promote apoptosis. These results prove that FGF19 amplification significantly inhibits the sensitivity of esophageal cancer cells to fluorouracil, and anlotinib can significantly enhance the sensitivity of fluorouracil to FGF19 amplified esophageal cancer cells. The combination of the two has a synergistic effect. Fig.12 The experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ns represents no statistical significance.
[0108] 3.7 Conclusion
[0109] We conducted functional experiments to understand the effect of FGF19 amplification on the malignant biological characteristics of esophageal cancer cells. The results showed that FGF19 gene amplification promoted the proliferation, migration and invasion of esophageal cancer cells and reduced the sensitivity of esophageal cancer cells to fluorouracil.
[0110] This part of the study showed that FGF19 amplification reduced the chemosensitivity of esophageal cancer cells to fluorouracil. Furthermore, this decreased chemosensitivity to fluorouracil could be reversed by anlotinib.
[0111] According to the present disclosure, all uses, products and methods disclosed and claimed herein can be prepared and implemented without excessive experimentation. Those skilled in the art can modify and change the technical solutions and contents disclosed in the present invention according to practical needs, but these modifications and changes do not deviate from the concept, spirit and scope of the present disclosure. All such modifications and changes are obvious to those skilled in the art and are within the scope of protection defined by the claims of the present application.
Claims
1. Use of a reagent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded by it in the preparation of a kit for evaluating and / or predicting the sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy, wherein compared with a control, an increased expression level and / or amplified copy number of the FGF19 gene indicates that the esophageal cancer cells or patients with esophageal cancer have a decreased sensitivity to fluorouracil chemotherapy.
2. The use according to claim 1, wherein the reagent for detecting the FGF19 gene or its mRNA or its encoded protein or protein fragment comprises a binding agent that binds to the protein or protein fragment encoded by the FGF19 gene, or a substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA.
3. The use according to claim 2, wherein the binding agent that binds to the protein or protein fragment encoded by the FGF19 gene is an anti-FGF19 antibody.
4. The use according to claim 2, wherein the substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA is a probe or an oligonucleotide primer.
5. A kit for evaluating and / or predicting the sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy, wherein the kit comprises a reagent for detecting the FGF19 gene or its mRNA or the protein or protein fragment encoded by it.
6. A kit according to claim 5, wherein the reagent for detecting the FGF19 gene or its mRNA or its encoded protein or protein fragment comprises a binding agent that binds to the protein or protein fragment encoded by the FGF19 gene, or a substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA.
7. The kit according to claim 6, wherein the binding agent that binds to the protein or protein fragment encoded by the FGF19 gene is an anti-FGF19 antibody.
8. The kit according to claim 6, wherein the substance that hybridizes with the FGF19 gene or its mRNA or amplifies the FGF19 gene or its mRNA is an oligonucleotide primer or a probe.
9. Use of anlotinib in the preparation of a drug for improving the sensitivity of esophageal cancer cells with FGF19 gene amplification or patients with esophageal cancer to fluorouracil chemotherapy.
10. The use according to any one of claims 1 to 4 or the kit according to any one of claims 5 to 8 or the use according to claim 9, wherein the esophageal cancer is esophageal squamous cell carcinoma or esophageal adenocarcinoma.
11. The use according to any one of claims 1-4 or the kit according to any one of claims 5-8 or the use according to claim 9, wherein the esophageal cancer is selected from recurrent esophageal cancer, metastatic esophageal cancer, recurrent metastatic esophageal cancer and advanced metastatic esophageal cancer.
